SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

NCATS Open Data2024-08-16 更新2026-08-08 收录

新冠疫苗研发

纳米颗粒疫苗临床试验

数据链接：

https://doi.org/10.1016/s2666-5247(23)00410-x 数据链接链接失效反馈

官方服务：

资源简介：

SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

创建时间：

2024-05-15

SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

资源简介：

相关数据集